KR960010681A - 17-데옥시코르티코스테로이드-21-(o)- 카복실산 에스테르, 이의 제조방법 및 이를 함유하는 약제 - Google Patents

17-데옥시코르티코스테로이드-21-(o)- 카복실산 에스테르, 이의 제조방법 및 이를 함유하는 약제 Download PDF

Info

Publication number
KR960010681A
KR960010681A KR1019950030850A KR19950030850A KR960010681A KR 960010681 A KR960010681 A KR 960010681A KR 1019950030850 A KR1019950030850 A KR 1019950030850A KR 19950030850 A KR19950030850 A KR 19950030850A KR 960010681 A KR960010681 A KR 960010681A
Authority
KR
South Korea
Prior art keywords
methyl
hydrogen
carboxylic acid
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019950030850A
Other languages
English (en)
Other versions
KR100406627B1 (ko
Inventor
슈타체 울리히
알페르만 한스-게오르크
본 만프레트
Original Assignee
로제르트, 루츠
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로제르트, 루츠, 훽스트 아크티엔게젤샤프트 filed Critical 로제르트, 루츠
Publication of KR960010681A publication Critical patent/KR960010681A/ko
Application granted granted Critical
Publication of KR100406627B1 publication Critical patent/KR100406627B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 다음 일반식(Ⅰ)의 17-데옥시코르티코스테로이드-21-[0]-카복실산 에스테르, 이의 제조방법 및 이를 함유한느 약제에 관한 것이다.
상기 식에서, A,Y,Z,R(1)및 R(2)는 명세서에서 정의한 바와 같다.
일반식(Ⅰ)의 화합물은 매우 강력한 국부 및 국소 소염 작용을 나타내며, 소염 효능의국부/전신 비가 매우우수하며, 종종 이 비는, 구조적으로 관련된, 21-에스테르 잔기에 어떠한 아릴 또는 헤트아릴 그룹도 수반하지 않는 코르티코이드 21-에스테르 또는 에스테르화되지 않은, 즉 유리21-하이드록실 그룹을 포함하는 유사한 17-뎅고시크르티코이드의 비에 의해 매우 우수하다.

Description

17-데옥시코르티코스테로이드-21-[0]-카복실산 에스테르, 이의 제조방법 및 이를 함유하는 약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 일반식 (Ⅰ)의 17-데옥시크로티코이드-21-카복실산 에스테르.
    상기 식에서, A는 임의의 입체 배열 상태로 존재하는 CHOH 및 CHCl, CH2, C=O 또는 9(11) 이중결합이고, Y는 수소, 불소 또는 염소이며, Z는 수소, 불소 또는 메틸이고, R(1)은 임의로 치환되거나 융합된 아릴 또는 헤트아릴이거나, 포화되거나, C2에서 1회 불포화되거나, C3에서 1회 이상 불포화되거나 또는 추가의 알킬그룹에 의해 환식으로 측쇄화되거나 헤테로 원자 O, S 또는 N에 의해 치환되거나 삽입된 [(C1-C4)-알킬][여기서, 1, 2위치는 포화되거나 불포화된(1,2-이중결합) 상태로 존재한다]이고, R(2)는 수소, α-메틸 또는 β-메틸이다.
  2. 제1항에 있어서, R(1)이 제1항에서 정의한 바와 동일하고, A가(β배열 상태로 존재하는)CHOH이고, Y가 F이며, Z가 수소이고, R(2)가 α-메틸인 17-데옥시코르티코이드-21-카복실산 에스테르.
  3. (a)일반식 (Ⅱ)의 화합물을 (a1) 일반식(Ⅲ)의 활성화 카복실산, 바람직하게는 할라이드 또는 무수물 또는 아졸리드와 반응시키거나 또는 (a2)탈수제 (DCCI등)의 존재하에 일반식(Ⅲ)의 카복실산 자체와 반응시키거나, (b)일반식(Ⅱ)의 화합물을 일반식 (Ⅲ)의 카복실산의 염, 바람직하게는 K또는 Na염 또는 트리알킬암모늄 염과 반응시켜 제1항에ㅣ서 청구한 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기 식에서, A는임의의 입체 배열 상태로 존재하는 CHOH 및 CHCl, CH2, C=O 또는 9(11) 이중결합이고, Y는 수소, 불소 또는 염소이며, Z는 수소, 불소 또는 메틸이고, R(1)은 임의로 치환되거나 융합된 아릴 또는 헤트아릴이거나, C2에서 1회 포화되거나,불포화되거나, C3에서 1회 이상 불포화되거나 또는 추가의 알킬그룹에 의해 환식으로 측쇄화되거나 헤테로원자 O, S또는 N에 의해 치환되거나 삽입된 [(C1-V4)-알킬][여기서, 1,2위치는 포화되거나 불포화되거나 불포화된 (1,2-이중결합) 상태로 존재한다.]이고, R(2)는 수소, α-메틸 또는 β-메틸이며, R(4)는 방법 (a)에서는 OH이고, 방법 (b)에서는 Br, I또는 설폰산 아릴 에스테르 그룹 또는 설폰산 알킬 에스테르 그룹이며, R(5)는 방법(a1)에서는 C1, Br, -O[-CO-[(C1-C4)알킬]-R(1)]1-,-OC(O)CF3또는 다른 활성 산 라디칼이고,방법(a2)에서는 OH이며, 방법(b)에서는 -[O-Me+](여기서, Me+는 바람직하게는 알칼리 금속염 또는 트리알킬암모늄 염의 양이온이다)이다.
  4. 제1항 에서 청구한 일반식(Ⅰ)의 화합물을 유효량 함유하는 약재.
  5. 약제학적으로 통상적인 첨가제와 배합된 제1항에서 청구한 일반식 (Ⅰ)의 화합물 유효량을 손상된 피부부위에 처리하여 피부 질환을 치료하는 방법.
  6. 피부 질환 치료용 약제를 제조하기 위한, 제 1항에서 청구한 일반식 (Ⅰ)의 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950030850A 1994-09-20 1995-09-20 17-데옥시코르티코스테로이드-21-[0]-카복실산에스테르,이의제조방법및이를함유하는약제 Expired - Fee Related KR100406627B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4433374.9 1994-09-20
DE4433374A DE4433374A1 (de) 1994-09-20 1994-09-20 17-Desoxi-corticosteroid-21-/O/-Carbonsäure- ester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
KR960010681A true KR960010681A (ko) 1996-04-20
KR100406627B1 KR100406627B1 (ko) 2004-02-19

Family

ID=6528610

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950030850A Expired - Fee Related KR100406627B1 (ko) 1994-09-20 1995-09-20 17-데옥시코르티코스테로이드-21-[0]-카복실산에스테르,이의제조방법및이를함유하는약제

Country Status (24)

Country Link
US (1) US5824670A (ko)
EP (1) EP0708111B1 (ko)
JP (1) JP3902255B2 (ko)
KR (1) KR100406627B1 (ko)
CN (1) CN1056151C (ko)
AT (1) ATE188480T1 (ko)
AU (1) AU695710B2 (ko)
CA (1) CA2158610C (ko)
CZ (1) CZ288297B6 (ko)
DE (2) DE4433374A1 (ko)
DK (1) DK0708111T3 (ko)
ES (1) ES2140596T3 (ko)
FI (1) FI114708B (ko)
GR (1) GR3032688T3 (ko)
HU (1) HU217438B (ko)
IL (1) IL115331A (ko)
NO (1) NO305210B1 (ko)
NZ (1) NZ280038A (ko)
PL (1) PL186071B1 (ko)
PT (1) PT708111E (ko)
RU (1) RU2161624C2 (ko)
SI (1) SI9500295B (ko)
TW (1) TW424094B (ko)
ZA (1) ZA957877B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12209988B2 (en) 2019-05-24 2025-01-28 Electronics And Telecommunications Research Institute Sensor and method of manufacturing the same

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2180216C2 (ru) * 2000-03-13 2002-03-10 Открытое акционерное общество "Биосинтез" Препарат, обладающий антимикробным и регенерирующим действием
CA2805832A1 (en) 2010-07-20 2012-01-26 Taro Pharmaceutical Industries Ltd. Process for the preparation of 17-desoxy-corticosteroids

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2755292A (en) * 1952-01-21 1956-07-17 Organon Labor Ltd Phenyl propionate of testosterone
US2783226A (en) * 1955-02-03 1957-02-26 Schering Corp Esters of cortical hormones
ES229413A1 (es) * 1956-06-22 1956-11-01 Francisco Vismara S P A UN PROCEDIMIENTO PARA LA PREPARACIoN DE COMPUESTOS ESTEROIDALES QUE CONTENGAN UN GRUPO CEToLICO EN LA CADENA LATERAL
DE1131668B (de) * 1959-07-16 1962-06-20 Leo Ab Verfahren zur Herstellung von Estern von Corticosteroid-Hormonen
CH495969A (de) * 1965-11-09 1970-09-15 Schering Ag Verfahren zur Herstellung neuer 21-Ester von 16a-Methyl-21-hydroxy- 1,4-steroiden
DE2047105C3 (de) * 1970-09-18 1979-02-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen 17-Chlorsteroide und Verfahren zu ihrer Herstellung
US3956349A (en) * 1975-02-18 1976-05-11 Syntex (U.S.A.) Inc. Process for preparing 3-enol ethers of 11β-hydroxy-Δ4 -pregnene-3-ones and derivatives thereof
FR2342738A1 (fr) * 1976-03-02 1977-09-30 Roussel Uclaf Nouveaux derives halogenes de la serie du 16a-methyl pregnane
DE2617655C2 (de) * 1976-04-21 1984-11-08 F. Hoffmann-La Roche & Co Ag, Basel Kortikoide, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE2645104C2 (de) * 1976-10-04 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen 11β-Hydroxy-1,4,8-pregnatrien-3,20-dion-Derivate und Verfahren zu ihrer Herstellung
FR2381065A2 (fr) * 1977-02-22 1978-09-15 Roussel Uclaf Nouveaux derives halogenes de la serie du 16 a-methyl pregnane
US4086254A (en) * 1977-04-13 1978-04-25 The Upjohn Company Photocleavable steroids
LU77457A1 (ko) * 1977-05-31 1979-01-19
US4377573A (en) * 1978-01-06 1983-03-22 Leveen Harry H Method of control of gastrointestinal bleeding
DE2817988A1 (de) * 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
DE2920726A1 (de) * 1979-05-18 1980-11-27 Schering Ag Neue kortikoide, ihre herstellung und verwendung
ATE3774T1 (de) * 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
ATE8790T1 (de) * 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
SE8303031D0 (sv) * 1983-05-30 1983-05-30 Leo Ab Improved steroid esters preparation
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
US4920114A (en) * 1988-06-28 1990-04-24 Merrell Dow Pharmaceuticals Inc. 19-fluoro- or cyano-21-hydroxyprogesterone derivatives useful as 19-hydroxylase inhibitors
NZ237559A (en) * 1990-04-02 1993-04-28 Merrell Dow Pharma Halogenoethyl steroid derivatives and pharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12209988B2 (en) 2019-05-24 2025-01-28 Electronics And Telecommunications Research Institute Sensor and method of manufacturing the same

Also Published As

Publication number Publication date
SI9500295B (en) 2001-12-31
CZ242595A3 (en) 1996-04-17
JP3902255B2 (ja) 2007-04-04
NZ280038A (en) 1997-03-24
ATE188480T1 (de) 2000-01-15
DE4433374A1 (de) 1996-03-21
DE59507565D1 (de) 2000-02-10
DK0708111T3 (da) 2000-06-13
PT708111E (pt) 2000-04-28
CN1124250A (zh) 1996-06-12
JPH0899992A (ja) 1996-04-16
FI954394L (fi) 1996-03-21
HUT72969A (en) 1996-06-28
CA2158610C (en) 2007-07-17
EP0708111A1 (de) 1996-04-24
HU217438B (hu) 2000-01-28
EP0708111B1 (de) 2000-01-05
RU2161624C2 (ru) 2001-01-10
HU9502735D0 (en) 1995-11-28
AU695710B2 (en) 1998-08-20
CA2158610A1 (en) 1996-03-21
PL186071B1 (pl) 2003-10-31
FI114708B (fi) 2004-12-15
ZA957877B (en) 1996-04-03
AU3172895A (en) 1996-04-04
PL310544A1 (en) 1996-04-01
CN1056151C (zh) 2000-09-06
GR3032688T3 (en) 2000-06-30
CZ288297B6 (en) 2001-05-16
NO305210B1 (no) 1999-04-19
KR100406627B1 (ko) 2004-02-19
IL115331A0 (en) 1995-12-31
ES2140596T3 (es) 2000-03-01
FI954394A0 (fi) 1995-09-18
SI9500295A (en) 1996-04-30
US5824670A (en) 1998-10-20
NO953695D0 (no) 1995-09-19
NO953695L (no) 1996-03-21
TW424094B (en) 2001-03-01
IL115331A (en) 2002-07-25

Similar Documents

Publication Publication Date Title
KR950005838A (ko) 코티코스테로이드 17- 알킬 카보네이트21-[0]-카복실산 및 카본산 에스테르, 이들의 제조방법 및 이들 화합물을 함유하는 약제
US3780177A (en) 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
DE3850676T2 (de) Hypotensive okulare Mittel.
DE2702553C2 (de) 9-Desoxy-6,9-epoxy-Δ↑5↑-PGF↓1↓↓α↓-derivate und Verfahren zu ihrer Herstellung
CH628356A5 (de) Verfahren zur herstellung neuer androstadien-17-carbonsaeureester.
KR920700209A (ko) 치환된 벤조[5,6]사이클로헵타피리딘의 헤테로사이클릭 n-옥사이드 유도체, 조성물 및 용도
KR970010784A (ko) 11-(치환된 페닐)-에스트라-4,9-디엔 유도체
KR950011463A (ko) 코티코이드-17,21-디카복실산 에스테르 및 코티코스테로이드 17- 카복실산 에스테르 21- 카본산 에스테르, 이들의 제조방법 및 이들 화합물을 함유하는 약제
EP0030377A1 (de) 9-Chlor-prostaglandinderivate, Verfahren zur Herstellung und Verwendung als Arzneimittel
NO158508C (no) Analogifremgangsmaate for fremstilling av antiinflammatorisk virksomme 4-pregnenderivater.
EP0198829A1 (de) 9-halogen-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
JPH09501943A (ja) 新規９−クロル−プロスタグランジン−誘導体
EP0215860A1 (de) 9-halogenprostaglandine, verfahren zu ihrer herstellung.
JPS6114159B2 (ko)
US4067991A (en) Pharmaceutical compositions and method of use for prostaglandin 1,11- and 1,15-lactones
EP0667160B1 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
PL95270B1 (ko)
EP0051558B1 (de) Prostacyclinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR960010681A (ko) 17-데옥시코르티코스테로이드-21-(o)- 카복실산 에스테르, 이의 제조방법 및 이를 함유하는 약제
US3723484A (en) 17-chloro steroids
US3691214A (en) 17-valerate ester of 6alpha,9alpha-difluoroprednisolone,its compositions and use as an anti-inflammatory agent
US5721273A (en) Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
FR2366311A1 (fr) Procede pour la preparation de steroides polyhalogenes utiles comme medicaments
KR970005316B1 (ko) 21-알콕시스테로이드 화합물
GB2232890A (en) Use of steroidal compounds as anti-fungal agents

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20121019

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20131017

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20141111

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20141111